| (Values in U.S. Thousands) | Dec, 2015 | Dec, 2014 | Dec, 2013 | Dec, 2012 | Dec, 2011 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -37,990 | -18,430 | -17,130 | -15,070 | -8,090 |
| Net Income Growth | -106.13% | -7.59% | -13.67% | -86.28% | unch |
Medgenics Inc Common Stock (MDGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Medgenics, Inc. is a medical technology and therapeutics company focused on providing sustained protein therapies. The Company's Biopump Platform Technology uses the patient's own tissue for the treatment of a range of chronic diseases. Its products include EPODURE focused on the treatment of chronic renal anemia and INFRADURE focused on the treatment of hepatitis C. Medgenics, Inc. is based in Vienna, Virginia.